Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

3 years ago

Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome  Tel Aviv, Israel / Vancouver, Canada, May…

Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System

3 years ago

Distinguished publisher and lecturer, Interventional Radiologist Prof. Francisco Cesar Carnevale Expected to Perform the World’s First Clinical Cases at the…

Assure Holdings Provides Corporate Update

3 years ago

Expects $3.3 Million Federal Tax Refund for Employee Retention Credit (ERC) Multi-Million Dollar Reimbursement Lawsuit Set for Jury Trial in…

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

3 years ago

PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat…

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

3 years ago

Southlake, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”),…

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

3 years ago

Recursion's Pipeline Recursion's internal pipeline as of Q1 2023Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry…

Conformis Reports First Quarter 2023 Financial Results

3 years ago

BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee…

Benitec Biopharma to Present at the OPMD International Conference

3 years ago

9 OPMD subjects are now enrolled on the Natural History (NH) StudyHAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec…

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

3 years ago

ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to…